Surufatinib combined with gemcitabine in soft tissue sarcoma (STS) patients failed with anthracyclines chemotherapy or monotherapy post-anlotinib progression: A multi-center, phase II trial
Latest Information Update: 14 Jan 2025
Price :
$35 *
At a glance
- Drugs Surufatinib (Primary) ; Gemcitabine
- Indications Leiomyosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 14 Jan 2025 New trial record